Related Experiment Video
Updated: Jul 15, 2026
Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
Published on: September 27, 2024
[Pharmacotherapeutic aspects of femoral head necrosis]
I H Tarner1, R Dinser, U Müller-Ladner
1Lehrstuhl für Innere Medizin mit Schwerpunkt Rheumatologie der Justus-Liebig Universität Giessen.
Insights
Drug therapy for avascular necrosis (AVN) of the hip can reduce pain and disability. Early intervention with medications like prostaglandins and bisphosphonates improves quality of life and may prevent joint replacement.
Area of Science:
- Orthopedics
- Pharmacology
Context:
- Avascular necrosis (AVN) of the hip remains a significant challenge in orthopedic treatment, particularly regarding effective drug interventions.
- Limited long-term studies explore pharmacological approaches for AVN management.
Purpose:
- To review the efficacy of various drug classes in managing avascular necrosis (AVN) of the hip.
- To highlight the potential of pharmacological treatments to mitigate disease progression and improve patient outcomes.
Summary:
- Investigated long-term drug therapies for hip AVN, including vasodilating agents (prostaglandins), anticoagulants, hormones, lipid-lowering drugs, and bisphosphonates.
- Studies indicate these medications significantly reduce pain, slow femoral head destruction, and decrease overall disability.
- Early-stage AVN treatment shows greater responsiveness to medication compared to later stages.
Impact:
- Pharmacological interventions can lead to a reduced need for hip replacement surgery in AVN patients.
- Effective drug therapy substantially improves the quality of life for individuals suffering from avascular necrosis of the hip.
Abstract:
Avascular necrosis (AVN) of the hip is one of the unsolved problems in orthopedics, especially with regard to drug therapy. Only a few studies exist using a long-term approach with vasodilating agents such as prostaglandins, anticoagulants, hormones, as well as lipid lowering and bone protective drugs such as bisphosphonates. However, using these medications several studies have demonstrated a significant reduction in pain, in the destruction of the femoral head as well as in overall disability. This resulted in a reduced need for joint replacement in patients with AVN and to a substantial improvement in quality of life. Of note, drug therapy should be initiated in the early phases of AVN as later stages appear to be less responsive to medication.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System